
Death confirmed from rare and deadly 'brain-eating amoeba' in southern lake
Prisma Health Richland Hospital in Columbia publicly confirmed the death on July 22, according to a statement from the South Carolina Department of Public Health (DPH) sent to Fox News Digital.
The patient died after exposure to Naegleria fowleri, a rare amoeba that causes a life-threatening brain infection called primary amebic meningoencephalitis (PAM).
"The July 2025 exposure to the organism Naegleria fowleri likely occurred at Lake Murray, but we cannot be completely certain, as this organism occurs naturally and is present in many warm water lakes, rivers and streams," the South Carolina DPH told Dox News Digital.
"Water activities like swimming or diving in warm freshwater areas, such as lakes and rivers, may increase the risk of exposure and infection."
Naegleria fowleri can be a risk when swimming in fresh water. The amoeba is most active in the months that the water temperature stays above 77F – July, August and September, the health official said.
Infection in humans is very rare, as this is the first case of Naegleria fowleri in South Carolina since 2016.
There is no increased risk to the public, as Naegleria fowleri is not transmissible person to person, according to the statement.
"Historically, one infection does not increase the chances that another will occur in the same body of water."
Fox News Digital previously spoke with Tammy Lundstrom, chief medical officer and infectious disease specialist for Trinity Health in Michigan, about the risks of infection.
"The risk of brain-eating amoeba is very low," she said. "Fewer than 10 people in the U.S. every year get infected — but unfortunately, most cases are fatal. There are only a handful of survivors of known cases."
The death rate for Naegleria fowleri exceeds 97%, per the CDC.
The initial symptoms of PAM usually begin about five days after exposure, but they can be noticed sooner.
Early signs usually include headache, nausea, fever and/or vomiting, the CDC's website states.
As the infection progresses, people may experience confusion, stiff neck, disorientation, hallucinations, seizures and coma.
"People usually start to feel ill one to 12 days after water exposure," Lundstrom said. "Early symptoms should prompt a medical evaluation, as they are also signs of bacterial meningitis."
Death can occur anywhere between one and 18 days of infection, at an average of five days.
To prevent potentially fatal infections, South Carolina health officials said it's important to know how and when exposure could be dangerous.
"How exposure occurs is when water forcefully enters the nose," the officials told Fox News Digital. "To reduce the risk of infection from Naegleria fowleri, hold your nose shut, use nose clips, or keep your head above water, and avoid jumping or diving into fresh water."
Lundstrom reiterated that it's best to avoid immersing your head in the water when swimming in summer.
"Infection occurs when water harboring the amoeba goes up a person's nose, usually during swimming," she previously told Fox News Digital. "It is not known why some people get infected and others, even swimming companions, do not."
Drinking contaminated water does not present a risk, and the infection does not spread from one person to another, Lundstrom added.
Because the amoeba is found in soil, the CDC also recommends avoiding stirring up the sediment at the bottom of lakes, ponds and rivers.
When a patient has been diagnosed with a brain-eating amoeba, treatment usually includes a variety of antifungal medications, as well as antibiotics like rifampin and azithromycin, according to Lundstrom.
Miltefosine, a newer antifungal drug, has been shown to kill Nagleria fowleri in laboratory tests and was used to treat some surviving patients, the CDC states on its website.
"However, the effect of all of these drugs on actual infected people is unknown due to the high fatality rate," Lundstrom noted.
Those who experience sudden headache, fever, stiff neck or vomiting — especially if they have recently been swimming in warm freshwater — should seek immediate medical attention, the CDC recommends.
For more Health articles, visit foxnews.com/health
Despite the infection's high fatality rate, Lundstrom emphasized the rarity of cases.
"Millions of people enjoy swimming every summer, but only a few become infected," she said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
5 Billion Sea Stars Have Shattered and Died Over the Past 10 Years, Scientists May Finally Know Why
A team of international researchers discovered the cause of a sea-star wasting diseaseNEED TO KNOW The cause of a sea star-wasting disease was determined to be a bacterium known as Vibrio pectenicida The disease causes sea stars to disintegrate to death in a white, goo-like substance An estimated 95% of sunflower sea stars died during the 10-year epidemicAfter an estimated 5 billion sea stars died due to a wasting disease in oceans globally, scientists have identified the root cause of the disease. A team of researchers identified the cause as a bacterium known as Vibrio pectenicida. The team reported its findings this week in Nature Ecology & Evolution. The disease causes starfish to disintegrate into a white, slimy substance. The disease is the largest documented epidemic for a noncommercial species, and it has affected more than 20 species of sea stars along the West Coast of North America, Scientific American reports. An estimated 90% of sunflower sea stars ( known as Pycnopodia helianthoides) have died from the illness, making them a critically endangered species. Sunflower sea stars are capable of sprouting 24 arms and growing to the size of a bicycle tire, per the Associated Press. The epidemic has lasted a decade. The same strain of bacteria has also infected shellfish. The international research project was led by scientists from the Hakai Institute, the University of British Columbia (UBC), and the University of Washington—and conducted in collaboration with The Nature Conservancy, the Tula Foundation, the U.S. Geological Survey's Western Fisheries Research Center, and the Washington Department of Fish and Wildlife. The first author on the study and an evolutionary ecologist at the Hakai Institute and UBC, Melanie Prentice, told Tula: "When we lose billions of sea stars, that really shifts the ecological dynamics.' Prentice went on to describe the impact of losing a sea star. 'In the absence of sunflower stars, sea urchin populations increase, which means the loss of kelp forests, and that has broad implications for all the other marine species and humans that rely on them," she explained. "So losing a sea star goes far beyond the loss of that single species.' Never miss a story — sign up for to stay up-to-date on the best of what PEOPLE has to offer, from celebrity news to compelling human interest stories. With the sharp decline in sea stars, the sea urchins that usually serve as a food source rapidly expanded in population. In turn, they ate nearly 95% of the kelp forests in Northern California within a decade. These kelp forests help provide food and habitats for a wide variety of marine life, including fish, sea otters and seals, per the AP. With these new findings, researchers are hoping to revive the sea star population and restore balance to the ecosystem, the outlet reported. Read the original article on People
Yahoo
6 hours ago
- Yahoo
FTC moves to block Edwards' JenaValve acquisition
This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. The Federal Trade Commission has moved to block Edwards Lifesciences' planned acquisition of JenaValve Technology, citing concerns that the deal threatens to reduce competition in the market for devices to treat aortic regurgitation. The agency alleged that over two days in July 2024, Edwards signed agreements to acquire both JenaValve and JC Medical, the two leading companies competing to bring transcatheter aortic valve replacement devices to market to treat the potentially fatal heart condition. Edwards closed the acquisition of JC Medical in August 2024. The FTC said Edwards' proposed $945 million acquisition of JenaValve would combine the only two companies conducting U.S. clinical trials for a TAVR aortic regurgitation, or TAVR-AR, device. 'The deal threatens to reduce competition in the TAVR-AR market, likely resulting in reduced innovation, diminished product quality, and potentially increased prices for consumers,' the agency stated in a federal court complaint. The commission voted 3-0 to issue an administrative complaint and seek a temporary restraining order and a preliminary injunction to halt the transaction pending an administrative proceeding. The complaint and injunction request were filed in the U.S. District Court for the District of Columbia. JenaValve is poised to become the first company to bring a TAVR-AR device, called Trilogy, to the U.S. market, the FTC said. Food and Drug Administration approval of a TAVR-AR device by another company besides Edwards and JenaValve is not expected in the foreseeable future. 'The FTC is taking action to stop this anticompetitive deal and ensure that JenaValve and Edwards' JC Medical subsidiary continue competing to innovate, expand treatment eligibility, and keep down costs,' Daniel Guarnera, director of the FTC's Bureau of Competition, said in the agency's Wednesday statement. Edwards' stance Edwards said Wednesday that it disagrees with the FTC's decision and believes it will limit the treatment options for patients with aortic regurgitation. Edwards argued that the acquisition will actually 'accelerate the availability, adoption and continued innovation of a life-saving treatment for patients suffering from AR.' The company plans to continue to pursue regulatory approval for the deal and expects a final determination by the end of the first quarter of 2026. JenaValve also said that it remains committed to completing the transaction and is confident in the rationale for the merger and the value it will bring to patients. The company intends to join Edwards to defend the case in court. Edwards increased its forecast for 2025 adjusted earnings per share to the high end of a range of $2.45 to $2.55, up from the high end of a range of $2.40 to $2.50, to reflect the impact of the FTC's action. The company said there is no impact to revenue guidance. Edwards agreed to pay $1.2 billion combined in July 2024 to buy JenaValve and Endotronix, which makes an implantable heart failure sensor. With the Endotronix transaction completed, Edwards was expecting the JenaValve deal to close in the middle of this year. Recommended Reading Edwards shrugs off tariffs, backs 2025 profit forecast
Yahoo
9 hours ago
- Yahoo
Navigating ADHICS Compliance: How MIT Consultants is Shaping Cybersecurity Standards in UAE Healthcare
Dubai, UAE,, Aug. 06, 2025 (GLOBE NEWSWIRE) -- As UAE healthcare and financial institutions race to meet stringent ADHICS regulations, MIT Consultants emerges as a trusted advisor, guiding enterprises toward robust compliance through tailored cybersecurity solutions. The cybersecurity landscape in the UAE has dramatically evolved, with healthcare and financial institutions facing heightened regulatory demands under the Abu Dhabi Healthcare Information and Cyber Security Standards (ADHICS). Recent high-profile data breaches and cyber threats have highlighted the urgent need for organizations to comply fully with these standards, protecting sensitive patient and financial information. As organizations scramble to adapt, MIT Consultants, a Dubai-based cybersecurity advisory and solutions reseller, is becoming a pivotal player in assisting healthcare and financial institutions in navigating the complexities of ADHICS compliance. Expert Advisors, Tailored Solutions MIT Consultants differentiates itself through its vendor-neutral advisory approach, ensuring that the solutions recommended are best suited to each organization's specific operational and compliance needs. Rather than advocating for a particular product, the firm's cybersecurity experts thoroughly analyze an institution's existing infrastructure, identify vulnerabilities, and align their recommendations precisely with ADHICS requirements. "Our role goes beyond mere reselling of cybersecurity solutions," says Mohamed Moussous, CEO of MIT Consultants. "We see ourselves as strategic partners. Our clients benefit from our ability to pinpoint precisely what's needed to achieve compliance efficiently and securely." Addressing Critical Cybersecurity Needs Healthcare and financial institutions face particular vulnerabilities—ransomware, phishing attacks, insider threats—all of which ADHICS compliance seeks to mitigate through rigorous cybersecurity measures. MIT Consultants addresses these threats by implementing robust Privileged Access Management (PAM), real-time threat detection systems, patch management processes, and secure information management strategies tailored specifically to ADHICS regulations. Real-World Successes MIT Consultants has successfully guided numerous institutions through ADHICS compliance by identifying gaps, providing detailed roadmaps, and recommending integrated solutions from global cybersecurity vendors. Their expertise ensures minimal operational disruption while achieving full regulatory adherence, ultimately safeguarding institutions from both cyber threats and potential regulatory penalties. "With our deep understanding of the UAE cybersecurity landscape, we provide not just technical solutions but peace of mind," adds Moussous. "Our clients trust us because we have their best interests at heart, which is compliance, security, and operational efficiency." A Strategic Advantage In an environment where regulatory compliance and cybersecurity intersect critically, MIT Consultants offers UAE healthcare and financial institutions a significant strategic advantage. By entrusting compliance initiatives to specialized cybersecurity advisors, organizations can stay ahead of threats, ensure adherence to regulations, and maintain a secure operational environment. As ADHICS continues to shape the future of cybersecurity compliance in the UAE, MIT Consultants stands out as an indispensable ally, turning complex regulatory challenges into clear, actionable strategies. Mohamed Moussous, CEO of MIT ConsultantsIRIS BAY - Business Bay Dubai Website: of the Group : CONTACT: mmoussous@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data